Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10214995 | 1.00 | GPR119 (0.41) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL288005 | 1.00 | GPR119 (0.41) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14791637 | 1.00 | GPR119 (0.41) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17992194 | 0.86 | GPR119 (0.41) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL11993158 | 0.84 | GPR119 (0.41) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14706990 | 0.82 | GPR119 (0.39) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13163063 | 0.81 | CHRNB2 (0.41) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14709891 | 0.79 | CHRNB2 (0.43) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12206738 | 0.79 | CHRNB2 (0.38) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19660256 | 0.78 | GPR119 (0.37) | GPR119CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072427-A1 | GPR 119 MODULATORS | PFIZER INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072427-A1 | GPR 119 MODULATORS | PFIZER INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072427-A1 | GPR 119 MODULATORS | PFIZER INC. | 2013-03-21 | — | — | US | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| EP-2504342-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | Pfizer Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2480551-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120095028-A1 | 3-OXA-7-AZABICYCLO[3.3.1]NONANES | PFIZER INC. | 2012-04-19 | — | — | US | disclosed |
| US-20120095028-A1 | 3-OXA-7-AZABICYCLO[3.3.1]NONANES | PFIZER INC. | 2012-04-19 | — | — | US | disclosed |
| WO-2011036576-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| WO-2010106457-A2 | 3-OXA-7-AZABICYCLO[3.3.1]NONANES | PFIZER INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106457-A2 | 3-OXA-7-AZABICYCLO[3.3.1]NONANES | PFIZER INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072427-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | GPR119 1/4885CHRNB2 271/4885CHRNA4 361/4885 |
| US-20120095028-A1 | 3-OXA-7-AZABICYCLO[3.3.1]NONANES | GPR119, GPR27, GPBAR1 | GPR119 1/4885CHRNB2 191/4885CHRNA4 260/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | GPR119 1/4885CHRNB2 271/4885CHRNA4 361/4885 |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | GPR3, GPR119, GPR84 | GPR119 2/4885CHRNB2 245/4885CHRNA4 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.